Trodelvy (sacituzumab govitecan-hziy) is a brand-name drug prescribed for certain breast cancers. It’s given as an intravenous (IV) infusion by a healthcare professional. The dosage can vary depending ...

Many Gilead Sciences investors have lost faith in Trodelvy in HR-positive, HER2-negative breast cancer after disappointing data on tumor progression. But the antibody-drug conjugate has now made a ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in ...

Thanks to a new FDA approval, Gilead Sciences’ Trodelvy has entered a breast cancer arena that’s crucial to the drug’s commercial success—as well as the company’s larger oncology ambitions. The FDA ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

A combo of two blockbuster breast cancer drugs was so successful in keeping an aggressive type of the disease from worsening, it is likely to change how young patients are treated, experts said after ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain kinds of breast cancer. This drug can interact with some other medications. For example, Trodelvy can interact with ...

– First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC – – Early Trend in Improvement in Overall ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

– Trodelvy Demonstrated 12.8 Months Overall Survival in Patients with Metastatic UC Whose Disease Progressed Rapidly Following Platinum-Based Chemotherapy – “The TROPHY-U-01 data show consistent ...

CHICAGO — The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared to chemotherapy in patients with the most common form of metastatic breast cancer — an outcome reported ...

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung ...